Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer

BACKGROUND: Accessible biomarkers are needed for immunotherapy in advanced non-small-cell lung cancer (NSCLC). We previously described a multivariate risk prediction model, the iSEND, which categorises advanced NSCLC patients treated with nivolumab into Good, Intermediate or Poor groups. This model...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Wungki, Mezquita, Laura, Okabe, Naoyuki, Chae, Young Kwang, Kwon, Deukwoo, Saravia, Diana, Auclin, Edouard, Planchard, David, Caramella, Caroline, Ferrara, Roberto, Agte, Sarita, Oh, Michael, Mudad, Raja, Jahanzeb, Mohammad, Suzuki, Hiroyuki, Besse, Benjamin, Lopes, Gilberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000664/
https://www.ncbi.nlm.nih.gov/pubmed/31761899
http://dx.doi.org/10.1038/s41416-019-0643-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000664/
https://www.ncbi.nlm.nih.gov/pubmed/31761899
http://dx.doi.org/10.1038/s41416-019-0643-y

Ejemplares similares